Healthtech funding in H1 2017
European Healthtech startup funding raised during H1 2017.
In H1 2017, 215 European Healthtech companies closed 229 funding rounds and raised €1.8B in equity funding (excluding debt and grants), up 67.1% versus H1 2016. Debt rounds added €7.0M. Israel led by capital raised, and Bpifrance was the most active investor. Data as of 20 Nov 2026.
Equity funding
€1.8B
+67.1% vs H1 2016 · excl. debt & grants · +€7.0M debt
Funding rounds
229
+35.5% vs H1 2016
Companies
215
Top country
Israel
Rank among sectors
#3
8.8% of sector funding
Debt financing
€7.0M
0.4% of total
Top-10 round share
35.5%
of disclosed capital
Rounds ≥ €100M
1
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H1 2017 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €158M | 28 |
| Feb | €62M | 21 |
| Mar | €192M | 30 |
| Apr | €799M | 74 |
| May | €359M | 47 |
| Jun | €195M | 29 |
Top countries
by € raisedHealthtech — top countries by capital, H1 2017 — interactive chart.
Data table
| Healthtech — top countries by capital, H1 2017 | |
|---|---|
| Israel | €385M |
| UK | €368M |
| Sweden | €251M |
| France | €226M |
| Switzerland | €158M |
| Germany | €153M |
| Spain | €68M |
| Ireland | €38M |
Stage mix
by € raisedHealthtech — stage mix, H1 2017 — interactive chart.
Data table
| Healthtech — stage mix, H1 2017 | |
|---|---|
| Other | €861M |
| Series A | €250M |
| Series D+ | €187M |
| Series B | €167M |
| Series C | €136M |
| Early VC | €82M |
| Growth/Late | €53M |
| Seed | €21M |
| Debt | €7.0M |
| Grant | €1.8M |
Exits & M&A
14 Acquisition · 1 IPO · 1 Merger16 exits · €362M disclosed.
| Zur Rose | IPO | Jan 2017 | €184M |
| Europa Apotheek | Acquisition | Feb 2017 | €126M |
| Crospon | Acquisition | May 2017 | €41M |
| Evoxx Technologies | Acquisition | Feb 2017 | €7.7M |
| Biotechware | Acquisition | May 2017 | €2.0M |
| Cipla Croatia | Acquisition | May 2017 | €1.0M |
Top deals
largest disclosed rounds in H1 2017| Company | Stage | Date | Amount |
|---|---|---|---|
| Insightec | Series D+ | Apr 2017 | €140M |
| Bima | Other | Apr 2017 | €91M |
| Biocartis | Other | Apr 2017 | €80M |
| Babylon | Other | Apr 2017 | €56M |
| Simba Sleep | Series B | Apr 2017 | €47M |
| Xeltis | Series C | Apr 2017 | €45M |
| Market Logic | Other | May 2017 | €45M |
| Breath Therapeutics | Series A | Mar 2017 | €44M |
| Impulse Dynamics | Other | May 2017 | €41M |
| Vivet Therapeutics | Series A | May 2017 | €38M |
| StarLeaf | Other | May 2017 | €37M |
| Doctolib | Other | Apr 2017 | €35M |
| Medlumics | Series B | Mar 2017 | €34M |
| ALung Technologies | Series C | Apr 2017 | €34M |
| Atlas Genetics | Series D+ | Jan 2017 | €32M |
Top investors
most active in H1 2017, by deal count- Bpifrance10 deals
- High-Tech Gründerfonds (HTGF)4 deals
- Horizon 20204 deals
- Ysios Capital4 deals
- ACT Venture Capital3 deals
- Go Capital3 deals
- Innogest Capital3 deals
- Invitalia Ventures3 deals
- Johnson & Johnson3 deals
- Kurma Partners3 deals